John Lunger Net Worth & Insider Trades

John Lunger - Chief Patient Supply Officer, Adaptimmune Therapeutics Plc

As of August 1, 2022

What is John Lunger's Net Worth?

The current estimated net worth of Adaptimmune Therapeutics Plc's Chief Patient Supply Officer, John Lunger, is estimated to be about $154.14K . John Lunger owns about 4,829 units of Adaptimmune Therapeutics Plc common stock. In the last 3 years at Adaptimmune Therapeutics Plc, John Lunger has sold an estimated value of $151.54K worth.

What is John Lunger's Past Insider Trading?

John Lunger's largest sale order was 4,823 units , worth over $44.61K on August 4, 2020. In total, John Lunger has made about 17 transactions over 3 years of their time at Adaptimmune Therapeutics Plc. John Lunger usually trades in January, with the busiest year in 2021 and 2022. The most recent transaction was a sale order of 2,983 units , worth over $5.29K on August 1, 2022.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What was John Lunger's Salary in 2020?

As Chief Patient Supply Officer of Adaptimmune Therapeutics Plc, John Lunger has a total base salary of $400,000 . John Lunger received compensation valued at about $1,487,463 in 2020 after becoming Chief Patient Supply Officer. The vast majority of their compensation came in the form of option awards of $857,661 , other earnings, plans or compensations of $198,000 , and other compensation of $31,802 .

What is John Lunger's' Mailing Address?

  • Mailing address is C/o Adaptimmune Therapeutics Plc 60 Jubilee Ave, Milton Park Abingdon, Oxfordshire X0 OX14 4RX United Kingdom

Adaptimmune Therapeutics Plc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Adrian Rawcliffe 2020 $574,000 $1,715,346 $378,840 $33,416 $2,701,602
Adrian Rawcliffe 2019 $500,481 $1,427,399 $177,251 $49,912 $2,155,042
Adrian Rawcliffe 2018 $457,011 $730,791 $174,807 $54,775 $1,417,384
Gavin Wood 2020 $337,065 $990,268 $166,847 $73,731 $1,567,911
Helen Tayton-Martin 2020 $454,940 $857,661 $225,195 $23,531 $1,561,327
Helen Tayton-Martin 2019 $435,949 $766,900 $137,324 $30,491 $1,370,664
Helen Tayton-Martin 2018 $408,308 $730,791 $156,178 $22,007 $1,317,284
William Bertrand 2020 $443,456 $857,661 $219,511 $30,485 $1,551,113
William Bertrand 2019 $432,640 $766,900 $136,282 $35,358 $1,371,180
William Bertrand 2018 $416,000 $685,114 $159,120 $35,070 $1,295,304
John Lunger 2020 $400,000 $857,661 $198,000 $31,802 $1,487,463
John Lunger 2019 $366,867 $435,546 $94,542 $35,655 $932,610
John Lunger 2018 $316,958 $602,909 $92,948 $35,07 $1,047,885
Michael Garone 2020 $217,000 - - - $217,000
Michael Garone 2019 $206,500 - - - $206,500
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm

What are Adaptimmune Therapeutics Plc's Past Insider Trades?

Adaptimmune Therapeutics Plc's most recent insider trade came on September 1, 2022 by Adrian Rawcliffe who sold 2,536 units worth $4.99K . In the last 6 years, insiders at Adaptimmune Therapeutics Plc have sold an estimated value of $40.15M and bought an estimated value of $526.78M worth of shares. Insider trading is most common in January, with the busiest year in 2018. The most active traders at the company are Adrian Rawcliffe, Chief Executive Officer,  John Lunger, Chief Patient Supply Officer,  and William Charles Bertrand, Chief Operating Officer .

Adaptimmune Therapeutics PLC Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1